Glaukos Corporation (GKOS): Price and Financial Metrics
GKOS Stock Summary
- GKOS's price/sales ratio is 18.43; that's higher than the P/S ratio of 89.06% of US stocks.
- With a year-over-year growth in debt of 272.86%, GLAUKOS Corp's debt growth rate surpasses 95.13% of about US stocks.
- Over the past twelve months, GKOS has reported earnings growth of 148.99%, putting it ahead of 90.29% of US stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to GLAUKOS Corp are PSTG, CLXT, CDNA, IQ, and ESTC.
- GKOS's SEC filings can be seen here. And to visit GLAUKOS Corp's official web site, go to www.glaukos.com.
GKOS Stock Price Chart Interactive Chart >
GKOS Price/Volume Stats
| Current price | $91.75 | 52-week high | $99.00 |
| Prev. close | $90.57 | 52-week low | $34.10 |
| Day low | $89.81 | Volume | 248,224 |
| Day high | $93.10 | Avg. volume | 426,033 |
| 50-day MA | $87.89 | Dividend yield | N/A |
| 200-day MA | $66.67 | Market Cap | 4.20B |
Glaukos Corporation (GKOS) Company Bio
Glaukos Corporation develops and commercializes products and procedures designed for the treatment of glaucoma. The company was founded in 1998 and is based in Laguna Hills, California.
Latest GKOS News From Around the Web
Below are the latest news stories about GLAUKOS Corp that investors may wish to consider to help them evaluate GKOS as an investment opportunity.
Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2021 financial results after the market close on Wednesday, May 5, 2021. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 5, 2021. |
Why Is Glaukos (GKOS) Down 7.1% Since Last Earnings Report?Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Glaukos to Support World Glaucoma Week with Patient Education Campaign and Free Screening InitiativesGlaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced two new patient-centric initiatives in honor of World Glaucoma Week. World Glaucoma Week is an annual global initiative championed by the World Glaucoma Association (WGA) to raise awareness surrounding the risk and prevalence of glaucoma. As a proud sponsor of the WGA, Glaukos is launching a global education and awareness campaign and collaborating with eye care institutions across the United States to offer free glaucoma screenings. Both programs are designed to increase glaucoma awareness, testing and diagnosis. |
Glaukos Announces Participation in Oppenheimer Healthcare ConferenceGlaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021, at 3:10 p.m. EDT. |
Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of DirectorsGlaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent. |
GKOS Price Returns
| 1-mo | 8.80% |
| 3-mo | 5.25% |
| 6-mo | 57.51% |
| 1-year | 169.77% |
| 3-year | 202.71% |
| 5-year | 397.29% |
| YTD | 21.91% |
| 2020 | 38.17% |
| 2019 | -3.03% |
| 2018 | 118.99% |
| 2017 | -25.22% |
| 2016 | 38.92% |
Continue Researching GKOS
Want to do more research on GLAUKOS Corp's stock and its price? Try the links below:GLAUKOS Corp (GKOS) Stock Price | Nasdaq
GLAUKOS Corp (GKOS) Stock Quote, History and News - Yahoo Finance
GLAUKOS Corp (GKOS) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...